Drug intelligence / Profile preview

ESN0115

Development stage: Preclinical
Lead developer: Beijing Yisheng Biotechnology
Modality: Cell Therapies
Administration: Implantation

Overview

ESN0115 is a preclinical cell therapy candidate developed by Beijing Yisheng Biotechnology (Essentia Biosciences) for the treatment of diabetes. The therapy utilizes 3D bioprinting technology to encapsulate islet cells within advanced biomaterials, creating a protective microenvironment. This encapsulation strategy is designed to shield the transplanted islet cells from the host's immune system and the harsh post-transplantation environment, thereby improving cell survival and functional longevity. By facilitating the successful engraftment of insulin-producing cells, ESN0115 aims to restore endogenous glycemic control in patients undergoing islet cell transplantation.

Other names: 3D Printed Islets3D打印胰岛

Beyond the preview

Go deeper on ESN0115.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ESN0115.

Explore the full profile